8/30/2007 10:39:29 AM
Liver Cancer Test Stopped Early
August 29, 2007 – Bayer and Onyx put an early stop to a Phase III trial of Nexavar in Asia-Pacific patients because of positive results. The trial was conducted among patients with hepatocellular carcinoma, the most common form of liver cancer. Nexavar extended all measures of survival. Asian regulators asked for the trial as a supplement to the filing for approval of Nexavar to prove the drug was safe and effective in this particular population. More details...
comments powered by